Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

Overview of attention for article published in PLOS ONE, January 2012

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 news stories from 2 outlets.

WALTHAM, Mass., Feb. 9, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company…

Summary Syndax's lead product, entinostat, was granted Breakthrough Therapy Designation by the FDA for advanced estrogen…